title: The current and future landscape of urinary thromboxane testing to evaluate atherothrombotic risk.
abstract: Biomarker testing for efficacy of therapy is an accepted way for clinicians to individualize dosing to genetic and/or environmental factors that may be influencing a treatment regimen. Aspirin is used by nearly 43 million Americans on a regular basis to reduce risks associated with various atherothrombotic diseases. Despite its widespread use, many clinicians are unaware of the link between suboptimal response to aspirin therapy and increased risk for inferior clinical outcomes in several disease states, and biomarker testing for efficacy of aspirin therapy is not performed as routinely as efficacy testing in other therapeutic areas. This article reviews the clinical and laboratory aspects of determining whole-body thromboxane production, particularly as it pertains to efficacy assessment of aspirin responsiveness.
authors: Sean-Xavier
authors: SX
authors: Neath
authors: John L
authors: JL
authors: Jefferies
authors: Jeffrey S
authors: JS
authors: Berger
authors: Alan H B
authors: AH
authors: Wu
authors: Joseph P
authors: JP
authors: McConnell
authors: Jeffrey L
authors: JL
authors: Boone
authors: Peter A
authors: PA
authors: McCullough
authors: Robert L
authors: RL
authors: Jesse
authors: Department of Emergency Medicine, University of California, San Diego, San Diego, CA; Advanced Heart Failure and Cardiomyopathy Services, Pediatric Cardiology and Adult Cardiovascular Diseases, and Division of Human Genetics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Medicine, and Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA; Health Diagnostic Laboratory, Richmond, VA; Boone Heart Institute, Denver, CO; Baylor Heart and Vascular Institute, Dallas, TX; Departments of Internal Medicine and Cardiology, Virginia Commonwealth University Health System, Richmond, VA, and Veterans Health Administration, Department of Veterans Affairs, Washington, DC; Department of Medicine, Division of Cardiovascular Medicine, University of California, San Diego and Director, Coronary Care Unit and Heart Failure Program, Veterans Affairs San Diego Healthcare System, San Diego, CA.
authors: Alan S
authors: AS
authors: Maisel
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D004351:Drug Resistance; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D018579:Patient Selection; D010979:Platelet Function Tests; D057285:Precision Medicine; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000652:urine*; D013931:Thromboxanes / Q000097:blood / Q000652:urine*; D016896:Treatment Outcome; D016482:Urinalysis
chemical_list: D015415:Biomarkers; D005343:Fibrinolytic Agents; D013931:Thromboxanes; D001241:Aspirin